235 related articles for article (PubMed ID: 34163161)
1. TMTP1-Modified, Tumor Microenvironment Responsive Nanoparticles Co-Deliver Cisplatin and Paclitaxel Prodrugs for Effective Cervical Cancer Therapy.
Jiang G; Wang X; Zhou Y; Zou C; Wang L; Wang W; Zhang D; Xu H; Li J; Li F; Luo D; Ma X; Ma D; Tan S; Wei R; Xi L
Int J Nanomedicine; 2021; 16():4087-4104. PubMed ID: 34163161
[TBL] [Abstract][Full Text] [Related]
2. Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer.
Liu B; Han L; Liu J; Han S; Chen Z; Jiang L
Int J Nanomedicine; 2017; 12():955-968. PubMed ID: 28203075
[TBL] [Abstract][Full Text] [Related]
3. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
[TBL] [Abstract][Full Text] [Related]
4. A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance.
Xiao H; Song H; Yang Q; Cai H; Qi R; Yan L; Liu S; Zheng Y; Huang Y; Liu T; Jing X
Biomaterials; 2012 Sep; 33(27):6507-19. PubMed ID: 22727463
[TBL] [Abstract][Full Text] [Related]
5. Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer.
He Z; Shi Z; Sun W; Ma J; Xia J; Zhang X; Chen W; Huang J
Tumour Biol; 2016 Jun; 37(6):7809-21. PubMed ID: 26695149
[TBL] [Abstract][Full Text] [Related]
6. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia.
Li Z; Zhang Y; Zhu C; Guo T; Xia Q; Hou X; Liu W; Feng N
Int J Pharm; 2020 Aug; 586():119576. PubMed ID: 32603839
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of platinum-taxane combination therapy in ovarian cancer.
Desale SS; Soni KS; Romanova S; Cohen SM; Bronich TK
J Control Release; 2015 Dec; 220(Pt B):651-9. PubMed ID: 26381902
[TBL] [Abstract][Full Text] [Related]
8. Construction and comparison of different nanocarriers for co-delivery of cisplatin and curcumin: A synergistic combination nanotherapy for cervical cancer.
Li C; Ge X; Wang L
Biomed Pharmacother; 2017 Feb; 86():628-636. PubMed ID: 28027539
[TBL] [Abstract][Full Text] [Related]
9. Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles.
Wang J
Drug Des Devel Ther; 2020; 14():823-832. PubMed ID: 32161442
[TBL] [Abstract][Full Text] [Related]
10. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.
Wang W; Xi M; Duan X; Wang Y; Kong F
Int J Nanomedicine; 2015; 10():3737-50. PubMed ID: 26045664
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
12. Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles.
Wu R; Zhang Z; Wang B; Chen G; Zhang Y; Deng H; Tang Z; Mao J; Wang L
Drug Des Devel Ther; 2020; 14():2249-2261. PubMed ID: 32606595
[TBL] [Abstract][Full Text] [Related]
13. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
Xu C; Liu W; Hu Y; Li W; Di W
Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
[TBL] [Abstract][Full Text] [Related]
14. Folate-modified, cisplatin-loaded lipid carriers for cervical cancer chemotherapy.
Zhang G; Liu F; Jia E; Jia L; Zhang Y
Drug Deliv; 2016 May; 23(4):1393-7. PubMed ID: 26165422
[TBL] [Abstract][Full Text] [Related]
15. Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery.
Aryal S; Hu CM; Zhang L
ACS Nano; 2010 Jan; 4(1):251-8. PubMed ID: 20039697
[TBL] [Abstract][Full Text] [Related]
16. Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo.
Chuan X; Song Q; Lin J; Chen X; Zhang H; Dai W; He B; Wang X; Zhang Q
Mol Pharm; 2014 Oct; 11(10):3656-70. PubMed ID: 25208098
[TBL] [Abstract][Full Text] [Related]
17. Preparation Of Nanobubbles Modified With A Small-Molecule CXCR4 Antagonist For Targeted Drug Delivery To Tumors And Enhanced Ultrasound Molecular Imaging.
Peng Y; Zhu L; Wang L; Liu Y; Fang K; Lan M; Shen D; Liu D; Yu Z; Guo Y
Int J Nanomedicine; 2019; 14():9139-9157. PubMed ID: 32063704
[TBL] [Abstract][Full Text] [Related]
18. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery.
Zhang L; Zhu D; Dong X; Sun H; Song C; Wang C; Kong D
Int J Nanomedicine; 2015; 10():2101-14. PubMed ID: 25844039
[TBL] [Abstract][Full Text] [Related]
19. Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment.
Cai L; Xu G; Shi C; Guo D; Wang X; Luo J
Biomaterials; 2015 Jan; 37():456-468. PubMed ID: 25453973
[TBL] [Abstract][Full Text] [Related]
20. Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy.
Zou L; Liu X; Li J; Li W; Zhang L; Fu C; Zhang J; Gu Z
Theranostics; 2021; 11(9):4171-4186. PubMed ID: 33754055
[No Abstract] [Full Text] [Related]
[Next] [New Search]
